Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022

Alessandro Brunelli; Amerikos Argyriou; Hasan Batirel; Yolonda Colson; Gail Darling; Felix Fernandez; Michael Gooseman; Toni Lerut; Daniela Molena; Nuria Novoa; Isabelle Opitz; Kostas Papagiannopoulos; G. Alexander Patterson; Rene H. Petersen; Janette Rawlinson; Gaetano Rocco; Brendon M. Stiles; Javeria Tariq; Gonzalo Varela

doi:10.21037/jtd-22-1550

Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022

Alessandro Brunelli
, Amerikos Argyriou
, Hasan Batirel
, Yolonda Colson
, Gail Darling
, Felix Fernandez
, Michael Gooseman
, Toni Lerut
, Daniela Molena
, Nuria Novoa
, Isabelle Opitz
, Kostas Papagiannopoulos
, G. Alexander Patterson
, Rene H. Petersen
, Janette Rawlinson
, Gaetano Rocco
, Brendon M. Stiles
, Javeria Tariq
, Gonzalo Varela

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	204-213
Number of pages	10
Journal	Journal of Thoracic Disease
Volume	15
Issue number	1
DOIs	https://doi.org/10.21037/jtd-22-1550
State	Published - Jan 2023

Keywords

Empathy
connection
lung cancer
patients
thoracic surgery
vulnerability

Access to Document

10.21037/jtd-22-1550

Cite this

Brunelli, A., Argyriou, A., Batirel, H., Colson, Y., Darling, G., Fernandez, F., Gooseman, M., Lerut, T., Molena, D., Novoa, N., Opitz, I., Papagiannopoulos, K., Patterson, G. A., Petersen, R. H., Rawlinson, J., Rocco, G., Stiles, B. M., Tariq, J., & Varela, G. (2023). Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022. Journal of Thoracic Disease, 15(1), 204-213. https://doi.org/10.21037/jtd-22-1550

@article{604ea180bc9546d6bac1c12ff7ba5b24,

title = "Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022",

keywords = "Empathy, connection, lung cancer, patients, thoracic surgery, vulnerability",

author = "Alessandro Brunelli and Amerikos Argyriou and Hasan Batirel and Yolonda Colson and Gail Darling and Felix Fernandez and Michael Gooseman and Toni Lerut and Daniela Molena and Nuria Novoa and Isabelle Opitz and Kostas Papagiannopoulos and Patterson, \{G. Alexander\} and Petersen, \{Rene H.\} and Janette Rawlinson and Gaetano Rocco and Stiles, \{Brendon M.\} and Javeria Tariq and Gonzalo Varela",

note = "Funding Information: Merck, and Genentech. IO reports that no real conflicts of interest are related to the work. The following could be perceived as such: Roche (Institutional Grant and Speakers Bureau), AstraZeneca (Advisory Board and Speakers Bureau), MSD (Advisory Board), BMS (Advisory Board), Medtronic (Institutional Grant), Intuitive (Proctorship). KP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease. RHP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease and is a member of the advisory board for AstraZeneca, Roche, MSD. RHP received speaker fee from Medtronic, AMBU, Medela, AstraZeneca. JR reports that she is involved with a number of lung cancer groups, charities and organisations in UK and Europe, as a patient partner in research/public patient partner voice. She holds no leadership roles e.g., Chair. The Patient public voice role is an equal member in the duties and responsibilities of those committees. All have policies of reimbursing travel/accommodation to ensure that nobody is left out of pocket by taking part in research. Some offer honoraria. Very few meetings have taken place in person during the pandemic in person therefore travel reimbursement has been minimal. Her CCG role was a fiduciary role as an equal member of the board. As an independent, she is repaid as an individual. GR received royalties from Scanlan International and he is a member of the advisory board for AstraZeneca. BMS received grants from Bristol Myers Squibb and Bristol Myers Squibb Foundation, and consulting fees from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Genentech, Arcus Biosciences, Galvanize Therapeutics, Medtronic. BMS is the inventor of patents TARGETING ART1 FOR CANCER IMMUNOTHERAPY (Patent Application Serial No. 63/307,502, filed February 7, 2022). BMS is a member of the Steering Committee for Medtronic for Medtronic, Data Safety Monitoring Board for Galvanize Therapeutics, Trial Steering Committee/Data Monitoring and Ethics Committee for RAMON study, Scientific Advisory Board for LUNGevity, Board and Vice Chair for Lung Cancer Research Foundation. BMS{\textquoteright}s spouse receives personal fees for salary from Xalud Therapeutics and owns stock, and options in Xalud Therapeutics, and stock in Pfizer. The other authors have no conflicts of interest to declare.",

year = "2023",

month = jan,

doi = "10.21037/jtd-22-1550",

language = "English",

volume = "15",

pages = "204--213",

journal = "Journal of Thoracic Disease",

issn = "2072-1439",

number = "1",

}

Brunelli, A, Argyriou, A, Batirel, H, Colson, Y, Darling, G, Fernandez, F, Gooseman, M, Lerut, T, Molena, D, Novoa, N, Opitz, I, Papagiannopoulos, K, Patterson, GA, Petersen, RH, Rawlinson, J, Rocco, G, Stiles, BM, Tariq, J & Varela, G 2023, 'Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022', Journal of Thoracic Disease, vol. 15, no. 1, pp. 204-213. https://doi.org/10.21037/jtd-22-1550

TY - JOUR

T1 - Sawubona reprise

T2 - reflections on the European Society of Thoracic Surgeons Presidential Address 2022

AU - Brunelli, Alessandro

AU - Argyriou, Amerikos

AU - Batirel, Hasan

AU - Colson, Yolonda

AU - Darling, Gail

AU - Fernandez, Felix

AU - Gooseman, Michael

AU - Lerut, Toni

AU - Molena, Daniela

AU - Novoa, Nuria

AU - Opitz, Isabelle

AU - Papagiannopoulos, Kostas

AU - Patterson, G. Alexander

AU - Petersen, Rene H.

AU - Rawlinson, Janette

AU - Rocco, Gaetano

AU - Stiles, Brendon M.

AU - Tariq, Javeria

AU - Varela, Gonzalo

N1 - Funding Information: Merck, and Genentech. IO reports that no real conflicts of interest are related to the work. The following could be perceived as such: Roche (Institutional Grant and Speakers Bureau), AstraZeneca (Advisory Board and Speakers Bureau), MSD (Advisory Board), BMS (Advisory Board), Medtronic (Institutional Grant), Intuitive (Proctorship). KP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease. RHP serves as an unpaid Editorial Board Member of Journal of Thoracic Disease and is a member of the advisory board for AstraZeneca, Roche, MSD. RHP received speaker fee from Medtronic, AMBU, Medela, AstraZeneca. JR reports that she is involved with a number of lung cancer groups, charities and organisations in UK and Europe, as a patient partner in research/public patient partner voice. She holds no leadership roles e.g., Chair. The Patient public voice role is an equal member in the duties and responsibilities of those committees. All have policies of reimbursing travel/accommodation to ensure that nobody is left out of pocket by taking part in research. Some offer honoraria. Very few meetings have taken place in person during the pandemic in person therefore travel reimbursement has been minimal. Her CCG role was a fiduciary role as an equal member of the board. As an independent, she is repaid as an individual. GR received royalties from Scanlan International and he is a member of the advisory board for AstraZeneca. BMS received grants from Bristol Myers Squibb and Bristol Myers Squibb Foundation, and consulting fees from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Genentech, Arcus Biosciences, Galvanize Therapeutics, Medtronic. BMS is the inventor of patents TARGETING ART1 FOR CANCER IMMUNOTHERAPY (Patent Application Serial No. 63/307,502, filed February 7, 2022). BMS is a member of the Steering Committee for Medtronic for Medtronic, Data Safety Monitoring Board for Galvanize Therapeutics, Trial Steering Committee/Data Monitoring and Ethics Committee for RAMON study, Scientific Advisory Board for LUNGevity, Board and Vice Chair for Lung Cancer Research Foundation. BMS’s spouse receives personal fees for salary from Xalud Therapeutics and owns stock, and options in Xalud Therapeutics, and stock in Pfizer. The other authors have no conflicts of interest to declare.

PY - 2023/1

Y1 - 2023/1

KW - Empathy

KW - connection

KW - lung cancer

KW - patients

KW - thoracic surgery

KW - vulnerability

UR - https://www.scopus.com/pages/publications/85146675846

U2 - 10.21037/jtd-22-1550

DO - 10.21037/jtd-22-1550

M3 - Editorial

C2 - 36794145

AN - SCOPUS:85146675846

SN - 2072-1439

VL - 15

SP - 204

EP - 213

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

IS - 1

ER -

Sawubona reprise: reflections on the European Society of Thoracic Surgeons Presidential Address 2022

Keywords

Access to Document

Other files and links

Cite this